Lisbon 2017 Delegate Registration Programme Exhibition Virtual Exhibition Satellites OneWorld Travel Discount
escrs app advert

Posters

Search Title by author or title

Aflibercept vs bevacizumab combined with phacoemulsification in patients with diabetic macular oedema

Poster Details

First Author: M.Zivkovic SERBIA

Co Author(s):    M. Zlatanovic   G. Zlatanovic   J. Djordjevic-Jocic   M. Radenkovic   S. Jovanovic        

Abstract Details

Purpose:

To compare the effects of the combination of aflibercept and phacoemulsification with the combination of bevacizumab and phacoemulsification on clinically significant diabetic macular edema in patients with non-proliferative diabetic retinopathy.

Setting:

The study was performed at the Ophthalmology Eye Hospital-Clinic Maja, Nis, Serbia, using the Cirrus SD OCT..

Methods:

The study included 21 patients with clinically significant DME who underwent combined phacoemulsification with 2mg dose of intravitreal aflibercept and 23 patients also with clinically significant DME who underwent the procedure of combined phacoemulsification and intravitreal bevacizumab application. Control medical check-ups included visual acuity (BCVA) and intraocular pressure measurements, fundus examination using Visucam 500 fundus camera, and macular OCT (optical coherence tomography) obtained with the Cirrus SD OCT device (Carl Zeiss Meditec, Dublin, CA, USA). Check-up examinations were performed at postoperative day 7, and then after one and three months.

Results:

Anatomical, as well as functional improvement was significant in both groups of patients. In the group of patients who received aflibercept preoperative central foveal thickness was 483+105.23 and after 3 months 305+133.42. In the group of patients who received bevacizumab preoperative central foveal thickness was 475+101.76 and after 3 months 320+130.78. In the group of patients who were treated with aflibercept, less reinjections were registered.

Conclusions:

The combination of phacoemulsification and intravitreal application of aflibercept and bevacizumab is a safe treatment option in patients with diabetic macular edema and cataract. Both drugs are equally efficient. The number of reinjections is lower in the application of aflibercept.

Financial Disclosure:

NONE

Back to Poster listing